Post-earnings recap
Reported
Tue, Aug 4, 2026
EPS actual
$4.27
EPS est.
$3.95
EPS surprise
+8.18%
1-day move
+3.57%
IDEXX Laboratories reported a strong earnings per share, beating expectations by over 8%. This positive surprise likely contributed to the stock's increase of 3.57% following the announcement. However, without revenue figures or management commentary, investors may need to wait for further details to fully understand the company's performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.27 | $3.93 | +8.18% |
| Revenue | N/A | $1.2B | N/A |
No transcript is on record, and the analysis is based on numerical results only.
IDEXX Laboratories, Inc. is a leading provider of diagnostic and information technology solutions for animal health and water testing. As part of the Health Care sector, IDEXX plays a crucial role in improving the health and well-being of pets and livestock, which is increasingly important in a world focused on animal welfare and food safety.
Last quarter
In Q1-2026, IDEXX reported an EPS of $3.47, exceeding expectations by 1.49%. The stock saw a slight decline of 0.03% the following day, indicating mixed investor sentiment.
Management promises and guidance
EPS beat streak
2Q
EPS beat rate
88%
Avg EPS surprise
+5.36%
Avg 1-day reaction
+6.45%
Analysts expect IDEXX to report strong earnings this quarter, driven by ongoing demand for its diagnostic solutions. The consensus EPS of $3.93 suggests confidence in the company's growth trajectory.
Bull case
If IDEXX beats expectations, it could signal strong demand for its products and potentially lead to upward revisions in future guidance.
Bear case
Conversely, if the company misses its EPS target, it may raise concerns about slowing growth in a competitive market.
Key metrics to watch
EPS
$3.93Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$1.2BRevenue growth reflects the company's ability to expand its market presence and customer base.
The print will turn on these.
Q1
Will EPS exceed $3.93, indicating strong demand for IDEXX's products?
A beat on EPS could reinforce confidence in the company's growth and lead to positive stock momentum.
Q2
What are the management's comments on revenue growth and future guidance?
Insights into revenue trends and future expectations will be critical for assessing the company's long-term prospects.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The Street may be underestimating the impact of IDEXX's recent product innovations, which could drive higher-than-expected demand.
Supporting evidence
The recent EPS beat rate of 75% indicates a strong track record of exceeding expectations.
Options pricing suggests a significant move, which may reflect investor sentiment that is more bullish than consensus.
IDEXX's commitment to technology investments could lead to unexpected revenue growth.
Key risk
If revenue growth exceeds $1.2B, it would challenge the current cautious consensus.
Pre-commit to what would confirm each case.
The market is closely watching IDEXX's ability to maintain growth in a competitive landscape, making these thresholds critical.
Bull confirmed if
An EPS of $4.00 or higher would confirm strong demand and operational efficiency.
Bear confirmed if
An EPS below $3.81 could signal weakening performance and lead to negative sentiment.
What the market is pricing for the move.
Implied Move
±17.90%
Historical Avg
±10.1%
The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.
Options are pricing ±17.9% while IDXX has averaged ±10.1% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
31.3%
Smart-money positioning from the most recent 13F filings.
Institutional
96.70%
of float
Insider
0.22%
of float
Holders
1,850
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
8,170,178 sh · $4.1B
10.37%
-2.3%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If IDEXX beats expectations, history suggests the stock could rise by around 8.77%, confirming strong demand.
In line / cautious
If results are in line but management is cautious, the stock may see a muted reaction as investors digest the commentary.
Miss
A miss could lead to a decline of about 0.73%, raising concerns about the company's growth trajectory.
The lines on the call that would change the story.
Vanguard Capital Management LLC
5,152,213 sh · $2.6B
6.54%
-0.6%
Vanguard Portfolio Management LLC
3,896,521 sh · $2.0B
4.95%
-0.4%
State Street Corporation
3,748,660 sh · $1.9B
4.76%
2.0%
Invesco Ltd.
3,611,416 sh · $1.8B
4.58%
7.8%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.